|
|
News Breaks | | | | October 15, 2012 | | 07:11 EDT |  | MRK, AZN, JNJ, LLY, BMY, GSK, RHHBY, PFE, SNY | Bristol Myers drug pipeline troubles results in trading declines, Bloomberg says
Bristol Myers Squibb (BMY) is the only U.S. drugmaker among the top 12 to decline in trading this year, and investors and analysts say they don’t expect a comeback in 2012 because of drug pipeline setbacks, reports Bloomberg. The company has fallen 6.1% this year, while the the Standard & Poor’s 500 Pharmaceutical Index has jumped 13%, Bloomberg says.Reference Link | |
|
News For JNJ;SNY;GSK;AZN;PFE;BMY;MRK;RHHBY;LLY From The Last 14 Days Check below for free stories on JNJ;SNY;GSK;AZN;PFE;BMY;MRK;RHHBY;LLY the last two weeks. |
|
|
| June 19, 2013 | | 09:38 EDT |  | MRK | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL AMAT FDX MA C GOOG DISH AMRN MRK BIDU | | | 08:45 EDT |  | RHHBY, JNJ | Leerink's biotech analyst holds analyst/industry conference call on ADA
Analyst Antlaffy, along with Dr. George Grunberger, founder & Chairman of the Grunberger Diabetes Institute, preview the upcoming American Diabetes Association's conference, including perspectives on new devices in diabetes, potential disruptive technologies at ADA and progress towards the artificial pancreas on an Analyst/Industry conference call to be held on June 20 at 2 pm. | | | 07:41 EDT |  | PFE | Pfizer holders should consider Zoetis exchange, says BMO Capital
BMO Capital thinks Pfizer (PFE) investors should consider participating in the Zoetis (ZTS) exchange as they have the opportunity to own Zoetis at around $29.40-$29.70 per share, which is 15% below BMO's valuation of $34 per share. Further, BMO thinks there is strong support for Zoetis below $30, which the firm feels lowers downside risk. BMO recommends that Pfizer investors tender around 20% of their shares into the exchange, noting that with the offer likely being oversubscribed, not all tendered shares will be converted to Zoetis. | | | 05:43 EDT |  | AZN, BMY | AstraZeneca, Bristol-Myers announce top line results of Phase 4 trial of Onglyza
 Subscribe for More Information | | | June 18, 2013 | | 16:00 EDT | | MRK | Options Update; June 18, 2013
Subscribe for More Information | | | 12:32 EDT | | AZN | AstraZeneca CEO says turnaround to take three or four years, Reuters reports
It will likely take three or four years for AstraZeneca's turnaround efforts to bear fruit, the company's CEO, Pascal Soriot, said today, according to Reuters. Reference Link | | | 10:17 EDT | | LLY | Lilly puts active on FDA says investigating two deaths after Zyprexa injections
Subscribe for More Information | | | 10:12 EDT | | LLY | FDA investigating two deaths of patients taking Lilly's Zyprexa
The FDA said in a safety announcement on its website that it is investigating two unexplained deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa. The patients died 3-4 days after receiving an appropriate dose of the drug, well after the 3-hour post-injection monitoring period required under the Zyprexa Risk Evaluation and Mitigation Strategy, the agency said. Both patients were found to have very high olanzapine blood levels after death. Eli Lilly is the maker of Zyprexa. | | | 09:38 EDT | | PFE | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM | | | 08:38 EDT | | SNY | Sanofi management to meet with JPMorgan
Subscribe for More Information | | | | 08:37 EDT | | GSK, MRK, AZN | Drug companies turn to microchips to test medicines, WSJ reports
Subscribe for More Information | | | 07:34 EDT | | JNJ | Medivation pullback a buying opportunity, says JPMorgan
Subscribe for More Information | | | 07:22 EDT | | AZN | Citigroup to host a conference
Subscribe for More Information | | | 07:13 EDT | | GSK | Aspen in talks buy GSK's Arixtra, Fraxiparine brands
Subscribe for More Information | | | 07:07 EDT | | GSK | GlaxoSmithKline receives offer for thrombosis brands from Aspen
GlaxoSmithKline said it received an offer for its thrombosis brands and Notre-Dame de Bondeville site from Aspen Global. A period of exclusivity has been agreed with Aspen. The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra and Fraxiparine brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees, GSK said. "The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline," the company added. | | | June 17, 2013 | | 16:20 EDT |  | JNJ | On The Fly: Closing Wrap
Stocks on Wall Street were higher following a session dominated by speculation over what is next for the Federal Reserve. The averages trimmed their gains after an article by the Financial Times suggested the Fed would signal a tapering of its pace of asset purchases at its Wednesday press conference. The upward trend resumed after the article's author said the report was based on opinion and that, "The Fed does not leak anything to any journalist to steer markets - especially during blackout." ECONOMIC EVENTS: In the U.S., the New York Fed Empire State Survey for June came in at 7.40, versus expectations for a 0 reading. The NAHB housing market confidence index for June rose to 52, versus the forecast for a more modest climb to 45 from its prior 44 reading. In Europe, Germany's Bundesbank said economic indicators for April pointed to robust growth in the second quarter and business sentiment improved in May, though warned of signs that growth in Europe's largest economy would slow over the summer. COMPANY NEWS: Netflix (NFLX) and DreamWorks (DWA) both climbed after announcing a major content deal. Under the agreement, DreamWorks will provide over 300 hours of content to Netflix, which the TV and movie service expects to start broadcasting next year. After the announcement, Netflix rose $15.24, or 7.12%, to $229.23, while DreamWorks added 93c, or 4.08%, to $23.74. MAJOR MOVERS: Among the notable gainers was Kandi Technologies (KNDI), up $1.53, or 24.4%, to $7.80 after saying it will deploy 5K-10K pure electric vehicles in China within the first year of launch. Also higher were shares of ViroPharma (VPHM), up $1.71, or 6.3%, to $28.87 after Reuters said the company has attracted takeover interest, though the company is not pursuing a sale. Among the noteworthy losers was Terex (TEX), down $2.45, or 7.72%, to $29.29 after the company lowered it fiscal year earnings view. Also lower was Medivation (MDVN), down $3.45, or 6.78%, to $47.41 after Johnson & Johnson (JNJ) acquired the company's competitor, privately held Aragon Pharmaceuticals. INDICES: The Dow was up 109.67, or 0.73%, to 15,179.85; the Nasdaq was up 28.57, or 0.83%, to 3,452.13; and the S&P 500 was up 12.31, or 0.76%, to 1,639.04. | | | 16:00 EDT | | PFE | Options Update; June 17, 2013
Subscribe for More Information | | | 12:29 EDT | | JNJ | On The Fly: Midday Wrap
Subscribe for More Information | | | 12:28 EDT | | JNJ | Medivation retreats after J&J beefs up prostate cancer slate
Subscribe for More Information | | | 12:08 EDT | | JNJ | J&J deal not negative for Medivation, says Citigroup
Subscribe for More Information | | |
|
|
|
|
|
|
